NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding NRX Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 1 | 18 | +17 |
| Shares | 320 | 1.64M | +1.64M (+511,739.4%) |
| Value | $4.00K | $18.9M | +$18.9M (+473,475.0%) |
New holders (17)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 637,416 | $7.41M | 0.00% |
| Linden Advisors LP | 364,352 | $4.23M | 0.02% |
| Owl Creek Asset Management, L.P. | 300,000 | $3.40M | 0.16% |
| Northern Trust Corp | 130,633 | $1.52M | 0.00% |
| HighPoint Advisor Group LLC | 43,501 | $505.0K | 0.05% |
| Morgan Stanley | 39,869 | $463.0K | 0.00% |
| Ionic Capital Management LLC | 35,721 | $415.0K | 0.05% |
| Geode Capital Management, LLC | 34,475 | $400.0K | 0.00% |
| Wolverine Asset Management LLC | 19,490 | $226.0K | 0.00% |
| Yakira Capital Management, Inc. | 11,923 | $139.0K | 0.02% |
| UBS Group AG | 8,385 | $97.0K | 0.00% |
| Royal Bank of Canada | 8,000 | $93.0K | 0.00% |
| Advisor Group Holdings, Inc. | 3,305 | $38.0K | 0.00% |
| Deutsche Bank AG | 200 | $2.00K | 0.00% |
| Citigroup Inc | 85 | $1.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 131 | $1.00K | 0.00% |
| Stonebridge Financial Planning Group, LLC | 80 | $1.00K | 0.00% |
Sold out (0)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
None.